Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea Q2 Roundup: New Drugs Drive Growth, First-Line Lazertinib Approval

New Indications For U-Turned Assets, 'Glocalization'

Executive Summary

Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.

You may also be interested in...



Video Roundtable: APAC Team Talks Key Regional Trends And Topics

Join the Pink Sheet's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.

Video Roundtable: APAC Team Talks Key Regional Trends And Topics

Join Scrip's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.

New Data Position Lazertinib As Strong Contender In 1L NSCLC

Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel